ASX vs NVDA

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a high valuation (P/E 38.78, Price/Book 8.44) despite solid recent earnings growth and strong 5-year price performance. While profitability and growth metrics are favorable, weak technical trend and inconsistent earnings surprises raise caution. The Graham Number of $5.08 suggests significant overvaluation, though growth-based intrinsic value of $11.15 supports a higher fair value.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.